27 Sep 2018 15:02
| 27 September 2018 | AIM: RENE |
ReNeuron Group plc
("ReNeuron" or the "Company")
Directors Share Purchases
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 27 September 2018 that, on the same day, the following purchases of the Company's ordinary shares of 1p each ("Ordinary Shares") were made by directors of the Company:
| Name | Title | Number of Ordinary Shares purchased | Total beneficial interest in the Company's Ordinary Shares | Percentage of Company's Total Voting Rights |
| Olav Hellebø | Chief Executive Officer | 14,936 | 21,630 | 0.068 |
| Michael Hunt | Chief Financial Officer | 7,462 | 27,546 | 0.087 |
ENQUIRIES:
| ReNeuron | +44 (0)20 3819 8400 |
| Olav Hellebø, Chief Executive Officer |
|
| Michael Hunt, Chief Financial Officer |
|
| Buchanan | +44 (0) 20 7466 5000 |
| Mark Court, Sophie Cowles, Tilly Abraham |
|
|
|
|
| Stifel Nicolaus Europe Limited | +44 (0) 20 7710 7600 |
| Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker) |
|
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to purchase of Ordinary Shares)
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Olav Hellebo | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Executive Officer | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | ReNeuron Group plc | ||||
| b) | LEI | N/A | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 0.01p
RENE - GB00B0DZML60 | ||||
| b) | Nature of the transaction | Purchase of ordinary shares | ||||
| c) | Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information
| N/A | ||||
| e) | Date of the transaction | 27 September 2018 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market | ||||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Michael Hunt | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Financial Officer | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | ReNeuron Group plc | ||||
| b) | LEI | N/A | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 0.01p
RENE - GB00B0DZML60 | ||||
| b) | Nature of the transaction | Purchase of ordinary shares | ||||
| c) | Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information
| N/A | ||||
| e) | Date of the transaction | 27 September 2018 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market | ||||
Reneuron (RENE)